Table 1.
Clinical and laboratory characteristics of patients at the time of diagnosis.
| Patient #1 | Patient #2 | Patient #3 | |
|---|---|---|---|
| Age (years) | 52 | 24 | 73 |
| Sex | Male | Male | Male |
| Comorbidities | None | CHD, HL | Hypertension, Diabetes, hyperlipidemia, coronary artery bypass grafting and IDA |
| Medications | None | Everolimus, Tacrolimus | Insulin, CardioaspirinAmlodipine, oral martial therapy. |
| Time from vaccination to admission | 21 days after the first dose (Astrazeneca) | 4 days after the second dose (Pfizer-BioNTech) | 2 days after the second dose (Pfizer-BioNTech) |
| Clinicalmanifestations | Oralbleeding, diffuse cutaneouspurpura | asymptomatic | petechiae on tongue and oral mucosa and ecchymoses on forearms and abdominal skin |
| Hb (g/dl) | 15.9 | 16.3 | 10.7 |
| PLT (cells/mm3) | 1,000 | 15,000 | 2,000 |
| WBC (cells/mm3) | 12,440 | 14,130 | 4,970 |
| INR (n.v. 0.8–1.2) | 0.99 | 1.2 | 1.02 |
| aPTT (n.v. 24–36 seconds) | 28 | 32 | 31 |
| D-dimer (n.v. 0–250 μg/L) | 236 | 220 | 146 |
| Fibrinogen (n.v. 170–400 μg/L) | 280 | 301 | 351 |
CHD=Congenital Heart Disease; HL= Hodgkin Lymphoma; IDA= Iron deficiency anemia; Hb=Hemoglobin; PLT=Platelet; WBC=White Blood Count; INR=International Normalized Ratio; aPTT= activated partial thromboplastin time;n.v.= normal values.